Overall, TMEM26 acts as a critical determinant for EMT in ESCC cells by disrupting TJ formation and promoting NF-κB signaling, which may be a potential therapeutic target for treating metastatic ESCC. The gene discussed is NFKB1; the disease is esophageal squamous cell carcinoma.